RATIONALE: Chlamydial lung infection has been associated with asthma in children and adults. However, how chlamydial infection influences the development of immune responses that promote asthma remains unknown. OBJECTIVES: To determine the effect of chlamydial infection at various ages on the development of allergic airway disease (AAD). METHODS: Mouse models of chlamydial lung infection and ovalbumin-induced AAD were established in neonatal and adult BALB/c mice. Neonatal or adult mice were given a chlamydial infection and 6 weeks later were sensitized and subsequently challenged with ovalbumin. Features of AAD and inflammation were compared between uninfected or unsensitized controls. MEASUREMENTS AND MAIN RESULTS: Mild Chlamydia-induced lung disease was observed 10-15 days after infection, as evidenced by increased bacterial numbers and histopathology in the lung and a reduction in weight gain. After 6 weeks, infection and histopathology had resolved and the rate of weight gain had recovered. Neonatal but not adult infection resulted in significant decreases in interleukin-5 production from helper T cells and by the numbers of eosinophils recruited to the lung in response to ovalbumin exposure. Remarkably, the effects of early-life infection were associated with the generation of both type 1 and 2 ovalbumin-specific helper T-cell cytokine and antibody responses. Furthermore, although neonatal infection significantly attenuated eosinophilia, the generation of the mixed T-cell response exacerbated other hallmark features of asthma: mucus hypersecretion and airway hyperresponsiveness. Moreover, infection prolonged the expression of AAD and these effects were restricted to early-life infection. CONCLUSIONS: Early-life chlamydial infection induces a mixed type 1 and 2 T-cell response to antigen, which differentially affects the development of key features of AAD in the adult.
RATIONALE: Chlamydial lung infection has been associated with asthma in children and adults. However, how chlamydial infection influences the development of immune responses that promote asthma remains unknown. OBJECTIVES: To determine the effect of chlamydial infection at various ages on the development of allergic airway disease (AAD). METHODS:Mouse models of chlamydial lung infection and ovalbumin-induced AAD were established in neonatal and adult BALB/c mice. Neonatal or adult mice were given a chlamydial infection and 6 weeks later were sensitized and subsequently challenged with ovalbumin. Features of AAD and inflammation were compared between uninfected or unsensitized controls. MEASUREMENTS AND MAIN RESULTS: Mild Chlamydia-induced lung disease was observed 10-15 days after infection, as evidenced by increased bacterial numbers and histopathology in the lung and a reduction in weight gain. After 6 weeks, infection and histopathology had resolved and the rate of weight gain had recovered. Neonatal but not adult infection resulted in significant decreases in interleukin-5 production from helper T cells and by the numbers of eosinophils recruited to the lung in response to ovalbumin exposure. Remarkably, the effects of early-life infection were associated with the generation of both type 1 and 2 ovalbumin-specific helper T-cell cytokine and antibody responses. Furthermore, although neonatal infection significantly attenuated eosinophilia, the generation of the mixed T-cell response exacerbated other hallmark features of asthma: mucus hypersecretion and airway hyperresponsiveness. Moreover, infection prolonged the expression of AAD and these effects were restricted to early-life infection. CONCLUSIONS: Early-life chlamydial infection induces a mixed type 1 and 2 T-cell response to antigen, which differentially affects the development of key features of AAD in the adult.
Authors: Malcolm R Starkey; Maximilian W Plank; Paolo Casolari; Alberto Papi; Stelios Pavlidis; Yike Guo; Guy J M Cameron; Tatt Jhong Haw; Anthony Tam; Ma'en Obiedat; Chantal Donovan; Nicole G Hansbro; Duc H Nguyen; Prema Mono Nair; Richard Y Kim; Jay C Horvat; Gerard E Kaiko; Scott K Durum; Peter A Wark; Don D Sin; Gaetano Caramori; Ian M Adcock; Paul S Foster; Philip M Hansbro Journal: Eur Respir J Date: 2019-07-18 Impact factor: 16.671
Authors: Emma L Beckett; Richard L Stevens; Andrew G Jarnicki; Richard Y Kim; Irwan Hanish; Nicole G Hansbro; Andrew Deane; Simon Keely; Jay C Horvat; Ming Yang; Brian G Oliver; Nico van Rooijen; Mark D Inman; Roberto Adachi; Roy J Soberman; Sahar Hamadi; Peter A Wark; Paul S Foster; Philip M Hansbro Journal: J Allergy Clin Immunol Date: 2013-02-04 Impact factor: 10.793
Authors: M R Starkey; D H Nguyen; A T Essilfie; R Y Kim; L M Hatchwell; A M Collison; H Yagita; P S Foster; J C Horvat; J Mattes; P M Hansbro Journal: Mucosal Immunol Date: 2013-09-18 Impact factor: 7.313
Authors: Cristiana C Garcia; Remo C Russo; Rodrigo Guabiraba; Caio T Fagundes; Rafael B Polidoro; Luciana P Tavares; Ana Paula C Salgado; Geovanni D Cassali; Lirlândia P Sousa; Alexandre V Machado; Mauro M Teixeira Journal: PLoS Pathog Date: 2010-11-04 Impact factor: 6.823
Authors: Justine Y Lau; Brian G Oliver; Melissa Baraket; Emma L Beckett; Nicole G Hansbro; Lyn M Moir; Steve D Wilton; Carolyn Williams; Paul S Foster; Philip M Hansbro; Judith L Black; Janette K Burgess Journal: PLoS One Date: 2010-10-13 Impact factor: 3.240
Authors: Y H Connie Leung; John M Nicholls; Chuk Kwan Ho; Sin Fun Sia; Chris K P Mok; Sophie A Valkenburg; Peter Cheung; Kenrie P Y Hui; Renee W Y Chan; Y Guan; S Akira; J S Malik Peiris Journal: J Gen Virol Date: 2014-05-30 Impact factor: 3.891